Table 2 Descriptive comparison of healthcare cost for the 12 months after the index event in CHF per patient
Mean (SD) | 95%-CI | Minimum | Maximum | |
|---|---|---|---|---|
Etanercept (n = 233) | ||||
Outpatient care | 1,113 (998) | 984-1,241 | 0 | 5,775 |
Medications | 17,751 (10,024) | 16,457-19,045 | 1,058 | 102,156 |
Laboratory tests | 585 (531) | 517-654 | 0 | 4,114 |
Outpatient care in hospitals | 453 (1,206) | 297-609 | 0 | 12,382 |
Devices and aids | 60 (220) | 32-89 | 0 | 1,827 |
Other claims | 593 (1,801) | 360-825 | 0 | 19,749 |
Total direct cost (etanercept) | 20,555 (10,740) | 19,169-21,942 | 1,589 | 111,994 |
Adalimumab (n = 201) | ||||
Outpatient care | 1,276 (965) | 1,142-1,410 | 0 | 5,798 |
Medications | 21,315 (9,008) | 20,062-22,568 | 1,169 | 58,129 |
Laboratory tests | 634 (521) | 561-706 | 0 | 4,840 |
Outpatient care in hospitals | 418 (891) | 294-542 | 0 | 5,913 |
Devices and aids | 90 (358) | 40-140 | 0 | 4,004 |
Other claims | 419 (810) | 306-531 | 0 | 7,241 |
Total direct cost (adalimumab) | 24,152 (9,403) | 22,844-25,460 | 1,994 | 61,613 |
Infliximab (n = 121) | ||||
Outpatient care | 1,087 (1,243) | 863-1,310 | 0 | 6,358 |
Medications | 22,666 (10,625) | 20,754-24,579 | 4,247 | 68,590 |
Laboratory tests | 1,024 (751) | 889-1,159 | 0 | 4,176 |
Outpatient care in hospitals | 2,363 (2,817) | 1,856-2,871 | 0 | 23,271 |
Devices and aids | 151 (258) | 104-197 | 0 | 1,722 |
Other claims | 323 (703) | 196-449 | 0 | 4,304 |
Total direct cost (infliximab) | 27,614 (11,860) | 25,479-29,748 | 5,733 | 72,233 |